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(NZB XNZW)F, (NZB/W F,) mice spontaneously develop a disease remarkably
similar to systemic lupus erythematosus (SLE) in humans (1) . The disease is
characterized by the appearance of antibodies to nuclear antigens and subsequent
development of a fatal, immune complex-mediated glomerulonephritis . In both
the human and murine forms of the disease, a strong association between major
histocompatibility complex (MHC) gene product genotype and manifestation of
the disease state have been reported . HLA-DRw2 and HLA-DRw3 individuals
are at higher risk than the general population for the development of SLE, while
in NZB/W F, (H-2d i'), a gene tightly linked to the H-2z haplotype contributes to
the renal disease (2-5) . The role of MHC genes in SLE and murine lupus is
unknown .
Several studies have demonstrated that in vivo administration of anti-la anti-
bodies to mice can greatly alter immune responsiveness (6-13, 17, 21) . We have
recently shown that in vivo treatment of H-2btk mice with anti-I-A k monoclonal
antibodies can suppress Immoral responses to (H,G)-A--L (controlled by I-Ak)
without markedly suppressing the response to (T,G)-A--L (controlled by I-Ab)
(13) . We have now extended these experiments to the treatment of the NZB/W
F,, a hybrid in which a gene derived from by the H-2' parent appears to
contribute to the development of a lupus-like nephritis . The results provide
evidence that in vivo administration of monoclonal antibodies specific for an 1
region gene product (I-.9`) of the H-2' haplotype induces a long-lasting remission
in female mice with moderate renal disease .
Materials and Methods
BriefDefinitive Report
Mice.
￿
NZB/W F, mice were bred in our mouse colony at Stanford University . Only
female mice between the ages of 4 and 5 mo with at least 1+ proteinuria were used .
Monocloiol Antibodies and Trentnteit Regimen.
￿
Two monoclonal antibodies were used in
these experiments . H10-3.6 is an IgG2a that fixes complement and reacts with public
specificity Ia.17 found on I-A""I . °"`1- products (20) . BP 107 (donated by Dr . F . Symington
and Dr . J . Sprent of the Wistar Institute, Philadelphia, PA) recognizes a public specificity
associated with I-A` and is an IgG, (19) . Hybridomas were maintained in ascites form and
the ascites fluids had titers >10' in cell-binding assays (13) .
NZB/W F, mice were treated for 4 mo with weekly intraperitoneal injections of 0.5 ml
of anti-I-A'- or anti-I-Ad-containing ascites, control ascites (Ig-containing ascites devoid of
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anti-I-A activity) or phosphate-buffered saline (PBS) . The mice were evaluated weekly for
changes in weight and proteinuria, and for mortality .
Protebmria .
￿
Proteinuria was assayed with tetrabromphenol paper (Albustix ; Ames Co .,
Inc ., Elkhart, IN) on fresh urine samples . The test is relatively specific for albumin and is
graded 1-4+ (1+, <30 mg/100 ml ; 2+, <100 mg/100 ml ; 3+, <300 mg/100 ml ; and 4+,
>2,000 mg/100 ml) . In these experiments, low grade proteinuria was designated as 1+
to 2+, and high grade proteinuria was designated as >2+ .
Results and Discussion
In two experiments, a total of 35 female NZB/W F, received H 10-3 .6 (anti-1-
A'), 25 received BP107 (anti-I-Ad), and, as controls, 10 received ascites fluid
containing no demonstrable anti-I-A Ig and 30 received PBS . All mice were 4-
5 mo old and had documented proteinuria at the beginning of the experiment .
Fig . I shows the improved survival rate of NZB/W F, females treated with anti-
I-A' antibody . At 1 yr, almost 90% of control animals were dead . Treatment
with anti-I-A' resulted in a highly significant improvement (P< 0.0001) in the
survival rate (90%) and anti-I-Ad therapy enhanced survival by 60% . High grade
proteinuria was observed in <10% of anti-I-A'-treated NZB/W F, mice com-
pared with 44% of surviving anti-I-Ad-treated animals and 70% of surviving
control animals (Fig . 2) .
A marked difference in weight gain of control and anti-I-A-treated mice was
also observed . The anti- I-A'-treated mice consistently gained or maintained
their weight throughout the experiments, while control animals showed fluctua-
tions in weight with a gradual decline as the disease progressed (data not shown) .
Significantly, this study showed that in vivo therapy with anti-I-A antibodies
can alter the course of NZB/W F, disease after onset of renal pathology . The
majority of experimental lupus studies are prophylactic in nature and therefore
have little applicability to the treatment ofSLE (22-29) . However, studies using
high dose cyclophosphamide, total lymphoid irradiation, and ribavirin have
demonstrated suppression of the disease after the development of proteinuria
(30-32) .
The mechanism by which anti-I-A therapy reverses NZB/W F, renal disease is
unknown . However, it probably involves altering the immune status of NZB/
W F, mice . Considerable evidence indicates that in vivo administration of anti-
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FIGURE 1 .
￿
Effect of anti-I-A monoclonal treatment on the survival ofNZB/NZW F, mice up
to I yr of age . (0) 10-3.6 (anti-I-A' .) group, (Q) BP107 (anti-I-Ad) group, (A) control group .
Arrows indicate the time period of monoclonal antibody treatment .1352 ADELMAN, WATLING, AND McDEVITT
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FIGURE 2.
￿
Effect of treatment on the cumulative progression to high grade proteinuria (2+ ,
!5100 mg/100 ml) up to 1 yr of age . (0) 10-3.6 (anti-I-A') group, (O) BP107 (anti-I-Ad), (A)
control group. Arrows indicate the time period of monoclonal antibody treatment .
la antibodies can markedly alter immune responsiveness . Studies demonstrate
that treatment with anti-la Ig can enhance allograft survival (6), modulate
immune responses to tumors (7, 8) and to schistosomes (9), block delayed
hypersensitivity reactions to azobenzenearsonate and a methylcholanthrene-
induced fibrosarcoma (10, 11), and prevent the induction of helper T cells
required for Ig secretion (12) . Further, results from our laboratory show that it
is possible to alter an Ir gene-controlled humoral response in a haplotype-specific
manner in F, mice by in vivo treatment with anti-I-A monoclonal antibodies
directed against theproduct ofone parental haplotype (13) . This in vivo regimen
results in an interesting form of suppression: it is long term, lasting at least 3 mo
after cessation of treatment ; it can alter ongoing I-A-controlled humoral re-
sponses ; and it has no significant effect on the response to an antigen that is not
controlled by the I-A allele under study (13, 14) . All of these factors are
advantages for any potential in vivo therapy . Results from adoptive transfer
studies indicate that this suppression is maintained by a suppressor T cell
population(s) (14) . The work of other investigators provides evidence that
suppressor cell induction may be a common occurrence after anti-la or anti-DR
(the human analog of Ia) administration . Broder et al . (15) identified an anti-
DR-induced T cell that can suppress mitogen-triggered Ig secretion in vitro,
while Muchmore et al . (16) were able to blockantigen-induced proliferation with
anti-DR-treated monocytes . Using an in vitro murine system, Berzofsky and
Richman (17) described transferable suppression of Ir gene-controlled responses
to myoglobin with anti-la-treated macrophages . Perry and Greene (18) showed
that aT cell population is responsible for depression of delayed hypersensitivity
and for tumor rejection seen in mice after in vivo anti-I-A treatment .
Experiments are in progress to determine if the induction of suppressor cells
is the mechanism responsible for the alteration in NZB/W F, renal disease after
anti-I-A treatment . It is possible that the anti-I-A may be affecting other la' cells
in NZB/W F, mice and that those actions may be responsible for alte"mg the
disease course . However, preliminary evidence indicates that anti-la monoclonals
are not functioning simply at the level of B cells, since anti-ds DNA and
antinuclear antibody titers are not reduced in the anti-I-A'-treated group relative
to the control group.ADELMAN, WATLING, AND McDEVITT
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The observed difference in the effectiveness of the anti-I-AZ and the anti-I-Ad
monoclonals to alter morbidity and mortality in the present experiments suggests
that the choice ofmonoclonal antibody may be critical . It is unclear whether this
variation resulted from differences in affinity, quantity, specificity, or isotype of
the antibodies used . It is unlikely that the experimental variation was due to
differences in affinity and quantity since both monoclonals had similar binding
potentials in solid-phase antigen-binding assays . Possibly, the reduced ability of
BPI07 to avert renal disease stems from its specificity ; i.e ., I-Ad gene product(s)
is not the principle product involved in the course of lupus nephritis . The work
of Knight andAdams (4) provides some support for this hypothesis . Their study
showed that three dominant or codominant genes are associated with glomeru-
lonephritis in NZB/W F, mice . Significantly, one of the two genes derived from
theNZW (H-2 z) parent is very tightly linked to the H-2 complex while the gene
derived from the NZB (H-2d) parent is weakly associated with H-2 and the
nephritis . Additionally, the isotype and the biological activity associated with
particular Ig subclassesmay be very important in alteringimmune responsiveness ;
i .e ., IgG, monoclonals may be less efficient than IgG2a antibodies in triggering
suppression .
The results of this study coupled with other reports (10-13, 21) indicate that
administration of anti-la antibodies is a safe method for manipulating immune
responses . In particular, NZB/W F, mice that are genetically prone to renal
difficulties tolerated weekly infusions of milligram quantities of Ig without
obvious problems . The ability of anti-I-A monoclonals to manipulate H-2-linked
autoimmune syndromes (21, 33) without visible damage to the host suggests that
the present experiments may have potential application to the treatment of
autoimmune diseases associated with certain HLA-D or DR types .
Summary
(NZB X NZW)F, mice spontaneously develop an autoimmune syndrome char-
acterized by a fatal immune complex glomerulonephritis . Administration of
monoclonal antibodies specific for an I region gene product (I-AZ) of the H-2
haplotype associated with susceptibility to glomerulonephritis in these animals
produced a remission in female mice with established renal disease . The results
demonstrated that anti-I-A therapy stabilized the level of proteinuria and in-
creased the 1-yr survival rate from 10% to >90% in treated animals relative to
control mice . These findings may ultimately have therapeutic potential for the
treatment of systemic lupus erythematosus.
Receivedfor publication 8August 1983.
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